Niemann-Pick Disease Type C (NPC) Market Insights, Epidemiology and Market Forecast, 2027 - ResearchAndMarkets.com

June 14, 2018

DUBLIN--(BUSINESS WIRE)--Jun 14, 2018--The “Niemann-Pick Disease Type C (NPC) - Market Insights, Epidemiology and Market Forecast-2027” drug pipelines has been added to ResearchAndMarkets.com’s offering.

The Report provides the current treatment practices, emerging drugs having the potential to get launched in the forecast period, market share of the individual therapies, current and forecasted market size of Niemann-Pick Disease Type C (NPC) from 2016 to 2027 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market.

The Niemann-Pick Disease Type C (NPC) market report gives the thorough understanding of the Niemann-Pick Disease Type C (NPC) by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends.

The Niemann-Pick Disease Type C (NPC) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed and treatable patient pool and their trends along with assumptions undertaken.

The disease epidemiology covered in the report is segmented by total prevalent patient population, diagnosed population, sub-types specific cases (NPC1 and NPC 2) and clinical distribution of NPC by phenotypes (early infantile, late infantile, juvenile and adult).

According to this research, the total prevalent population of NPC was found to be 2,099 in the year 2016 in 7MM.

Key Topics Covered:

1. Key Insights

2. Niemann-Pick Disease Type C (NPC) Market Overview at a Glance

2.1. Market Share (%) Distribution of Niemann-Pick Disease Type C (NPC) in 2016

2.2. Market Share (%) Distribution of Niemann-Pick Disease Type C (NPC) in 2027

3. Disease Background and Overview: Niemann-Pick Disease Type C (NPC)

3.1. Introduction

3.2. Classification of Niemann Pick Disease

3.3. Causes

3.4. Inheritance patterns

3.5. Clinical Manifestations

3.6. Pathophysiology

3.7. Diagnosis

4. Epidemiology and Patient Population

4.1. Key Findings

4.2. 7MM Total Prevalent Patient Population of Niemann Pick Disease Type-C

5. Country Wise-Epidemiology of NPC

6. Treatment Practices

6.1. Treatment Goals

6.2. Treatment Algorithm

6.3. NP-C Guidelines Working Group: Treatment Recommendations

7. Unmet Needs

8. Marketed drugs

8.1. Zavesca: Actelion Pharmaceuticals Ltd

9. Emerging drugs

9.1. Emerging Drugs Analysis

9.2. Arimoclomol: Orphazyme

9.3. VTS-270: Vtesse Inc. (Mallinckrodt)

9.4. Trappsol Cyclo (cyclodextrin): CTD Holdings, Inc.

10. Niemann Pick Disease Type C: 7 Major Market Analysis

10.1.1. Key Findings

10.1.2. Total Market Size of Niemann Pick Disease Type C in 7MM

10.1.3. Market Size by Therapeutic Class in 7MM

10.1.4. Market Size by Therapies in 7MM

11. Market Outlook by Country

12. The United States: Market Outlook

13. EU-5 Countries: Market Outlook

14. Japan: Market Outlook

15. Market Drivers

16. Market Barriers

17. Appendix

18. Capabilities

Companies Mentioned

Actelion Pharmaceuticals Ltd Orphazyme Vtesse Inc. (Mallinckrodt) CTD Holdings, Inc.

For more information about this drug pipelines report visit https://www.researchandmarkets.com/research/wvj2kt/niemannpick?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20180614006210/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Endocrine and Metabolic Disorders Drugs



SOURCE: Research and Markets

Copyright Business Wire 2018.

PUB: 06/14/2018 04:21 PM/DISC: 06/14/2018 04:21 PM


Update hourly